Status:
UNKNOWN
A PILOT Study on LSGB vs EMB in the Diagnosis of Cardiac Transthyretin Amyloidosis
Lead Sponsor:
Unity Health Toronto
Collaborating Sponsors:
Pfizer
Conditions:
Amyloidosis
Eligibility:
All Genders
18-96 years
Brief Summary
Transthyretin (TTR) is a plasma protein mainly synthesized in the liver, recognized as a transporter of thyroxine and retinol-binding protein. Unstable changes in two types of TTR (wild type or varian...
Detailed Description
We propose broad eligibility criteria to increase the generalizability and feasibility of the proposed study. Patients who are confirmed diagnosis of Amyloid Transthyretin Cardiomyopathy - wild type (...
Eligibility Criteria
Inclusion
- Patients who are confirmed diagnosis of Amyloid Transthyretin Cardiomyopathy - wild type (ATTRwt) through Echocardiography, Cardiac Magnetic Resonance Imaging, pyrophosphate scan, and genetic testing and had an endomyocardial biopsy (or will undergo endomyocardial biopsy).
Exclusion
- Patients who had negative amyloid deposits in the endomyocardial biopsy.
Key Trial Info
Start Date :
June 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05375279
Start Date
June 15 2022
End Date
March 31 2023
Last Update
May 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
London Health Sciences Centre
London, Ontario, Canada, N6A 5A5